JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Relevant concepts of functioning for patients with systemic lupus erythematosus identified in a delphi exercise of experts and a literature review.
Arthritis Care Res (Hoboken)
PUBLISHED: 05-13-2014
Show Abstract
Hide Abstract
Objective. To identify in a Delphi exercise of international SLE experts and a systematic literature review the most relevant concepts that impact on the functioning of SLE patients Methods. Sixty SLE experts participated in all rounds of a three round e-mail-based Delphi exercise; for the literature review, 573 manuscripts out of four decades were analysed. Concepts in the first Delphi round and from the literature were linked to categories of the International Classification of Function (ICF). Categories were voted on individually in a feedback-driven Delphi process, and ranked by frequency in the literature, respectively. Results. In the Delphi exercise, at least 80% of the participants found 30 categories of the domain body functions and structures and three in the domains activities and participation and environmental factors important. In general, the categories identified in the literature review overlapped with those in the Delphi exercise with regard to body functions and structures, while showing some differences in other domains. The highest agreement concerned the ICF categories "joints", "skin and related structures", "fatiguability", "immunological system functions", and "handling stress and other psychological demands". Agreement with an earlier patient Delphi exercise was considerable. Conclusion. A three step Delphi exercise of sixty SLE experts and a literature review identified a wide spectrum of relevant ICF categories with impact on functioning of SLE patients. The categories derived from these approaches overlap with each other and with those of a patient Delphi exercise. © 2014 American College of Rheumatology.
Related JoVE Video
Treat-to-target in systemic lupus erythematosus: recommendations from an international task force.
Ann. Rheum. Dis.
PUBLISHED: 04-16-2014
Show Abstract
Hide Abstract
The principle of treating-to-target has been successfully applied to many diseases outside rheumatology and more recently to rheumatoid arthritis. Identifying appropriate therapeutic targets and pursuing these systematically has led to improved care for patients with these diseases and useful guidance for healthcare providers and administrators. Thus, an initiative to evaluate possible therapeutic targets and develop treat-to-target guidance was believed to be highly appropriate in the management of systemic lupus erythematosus (SLE) patients as well. Specialists in rheumatology, nephrology, dermatology, internal medicine and clinical immunology, and a patient representative, contributed to this initiative. The majority convened on three occasions in 2012-2013. Twelve topics of critical importance were identified and a systematic literature review was performed. The results were condensed and reformulated as recommendations, discussed, modified and voted upon. The finalised bullet points were analysed for degree of agreement among the task force. The Oxford Centre level of evidence (LoE, corresponding to the research questions) and grade of recommendation (GoR) were determined for each recommendation. The 12 systematic literature searches and their summaries led to 11 recommendations. Prominent features of these recommendations are targeting remission, preventing damage and improving quality of life. LoE and GoR of the recommendations were variable but agreement was >0.9 in each case. An extensive research agenda was identified, and four overarching principles were also agreed upon. Treat-to-target-in-SLE (T2T/SLE) recommendations were developed by a large task force of multispecialty experts and a patient representative. It is anticipated that 'treating-to-target' can and will be applicable to the care of patients with SLE.
Related JoVE Video
Rituximab therapy in patients with refractory dermatomyositis or polymyositis: differential effects in a real-life population.
Rheumatology (Oxford)
PUBLISHED: 04-04-2014
Show Abstract
Hide Abstract
While a double-blind trial has not met its endpoint, rituximab (RTX) is still seen as useful in refractory DM and PM. In this study we analysed the charts of all patients receiving RTX for myositis in our institutions for objective outcome parameters.
Related JoVE Video
Withdrawal of therapy in non-renal systemic lupus erythematosus: is this an achievable goal?
Clin. Exp. Rheumatol.
PUBLISHED: 09-10-2013
Show Abstract
Hide Abstract
Survival of patients with systemic lupus erythematosus (SLE) has greatly improved over the decades. Many reasons for treatment withdrawal may be faced by the physician during the disease course, such as inactivity of disease, damage accrual, risks of long-term side effects, or potential interactions with other drugs required to treat concomitant conditions, as well as patients preferences. Therefore, analysis of long-term therapy and treatment withdrawal is important. We have examined the available literature concerning withdrawal of therapy, with attention to glucocorticoids, antimalarial drugs and traditional immunosuppressive drugs in SLE patients who did not have renal disease. We expanded our search to address two questions: i) advantages of long-term therapy in SLE (i.e. reduction of flares, reduction of damage accrual, improved survival); and (ii) burden/side effects of therapy in SLE. Studies are needed to: i) define remission in SLE; ii) define the advantages of long-term therapy in non-renal lupus in terms of prevention of flares; iii) clarify the risks related with long-term immunosuppressive therapy; iv) identify the appropriate patient at the appropriate time for withdrawal of corticosteroids or immunosuppressive therapy; and v) define withdrawal/tapering strategies.
Related JoVE Video
A 3-day delay in synovial fluid crystal identification did not hinder the reliable detection of monosodium urate and calcium pyrophosphate crystals.
J Clin Rheumatol
PUBLISHED: 07-23-2013
Show Abstract
Hide Abstract
Arthrocentesis is an essential emergency step in managing patients with acute arthritis. To identify a bacterial infection, Gram staining is performed promptly. However, crystal analysis may not be immediately performed in many facilities. Being considered not to be stable over time, synovial fluid (SF) is sometimes discarded instead of being stored for crystal identification.
Related JoVE Video
Low risk of renal flares and negative outcomes in women with lupus nephritis conceiving after switching from mycophenolate mofetil to azathioprine.
Rheumatology (Oxford)
PUBLISHED: 02-04-2013
Show Abstract
Hide Abstract
MMF is teratogenic and needs to be replaced before pregnancy. This change may lead to flares. Our aim was to determine the risk of renal flares in women with LN who switched treatment from MMF to AZA before conception and to evaluate the outcome of their pregnancies.
Related JoVE Video
Lots of autoantibodies equal lupus?
Arthritis Res. Ther.
PUBLISHED: 01-22-2013
Show Abstract
Hide Abstract
ABSTRACT: Autoantibodies may be found years before an autoimmune disease becomes clinically apparent. For systemic lupus erythematosus (SLE), those to RNA-binding proteins, to phospholipids, and to double-stranded DNA, in particular, have been found in sera of SLE patients years before the diagnosis was made. New data now show in an unbiased way that, in patients with early SLE, no single antibody class or specificity is associated with progression to SLE. Rather, an increasing number of autoantibody specificities, such as to thyroid antigens, was observed in patients progressing. This points to more generalized B cell autoreactivity during progression to SLE, underlying lupus disease manifestations.
Related JoVE Video
Performance of the new 2011 ACR/EULAR remission criteria with tocilizumab using the phase IIIb study TAMARA as an example and their comparison with traditional remission criteria.
Ann. Rheum. Dis.
PUBLISHED: 08-29-2011
Show Abstract
Hide Abstract
Remission is the established goal in rheumatoid arthritis (RA) treatment. Although originally defined by a disease activity score in 28 joints (DAS28) <2.6, more stringent criteria may imply the absence of disease activity. The 2011 ACR/EULAR remission criteria provide the newest and most stringent definition of remission.
Related JoVE Video
Therapeutic blockade of TNF in patients with SLE-promising or crazy?
Autoimmun Rev
PUBLISHED: 05-03-2011
Show Abstract
Hide Abstract
TNF is an important mediator of inflammation, but is also involved in the control of autoimmunity. The latter has been demonstrated in a murine model of SLE (NZB/W) and by the occurrence of autoantibodies to nuclear antigens as well as occasional, transient lupus-like syndromes in patients under TNF blockade. In contrast, data on increased TNF levels in serum, kidney and skin samples of SLE patients as well as results in other mouse models of the disease point to an inflammatory role of TNF in SLE organ disease. Despite all due caution, given these two sides of the cytokine, TNF blockade has by now been employed for several years in single cases and open label studies; data on more than fifty patients have meanwhile been published, for the vast majority of which infliximab was employed. These clinical data have to be very cautiously interpreted, as always with data on single cases or open label trials. However, some consistent pieces of information emerge and may inform controlled clinical trials: (i) While antibodies to double-stranded DNA commonly showed transient increases, lupus flares have not been seen so far and thus apparently are at least not the rule; (ii) in contrast, increases in anti-phospholipid antibodies may be associated with vascular adverse events; (iii) bacterial infections, pneumonia and urinary tract infections in particular, have been observed; (iv) short term induction therapy appears relatively safe, while long-term TNF blockade may confer significant risks in SLE; (v) TNF blocker induction therapy may lead to long-term remission in patients with lupus nephritis, hemophagocytic syndrome, and interstitial lung disease; (vi) patients with lupus arthritis often respond to TNF-blockade but symptoms recur after cessation of therapy, necessitating longer term therapy, which is more risky than short term treatment.
Related JoVE Video
Safety and clinical outcomes of rituximab therapy in patients with different autoimmune diseases: experience from a national registry (GRAID).
Arthritis Res. Ther.
PUBLISHED: 03-28-2011
Show Abstract
Hide Abstract
Evidence from a number of open-label, uncontrolled studies has suggested that rituximab may benefit patients with autoimmune diseases who are refractory to standard-of-care. The objective of this study was to evaluate the safety and clinical outcomes of rituximab in several standard-of-care-refractory autoimmune diseases (within rheumatology, nephrology, dermatology and neurology) other than rheumatoid arthritis or non-Hodgkins lymphoma in a real-life clinical setting.
Related JoVE Video
Tophaceous gout and renal insufficiency: a new solution for an old therapeutic dilemma.
Case Rep Med
PUBLISHED: 02-24-2011
Show Abstract
Hide Abstract
The prevalence of gout is increasing with increased life expectancy. Approximately half of the patients with gout have some degree of renal impairment. If both conditions persistently coexist, and in severe tophaceous gout, in particular, treatment has been difficult. We here report on the case of an 87-year-old woman, who had been suffering from recurrent gouty arthritis over 4 years. Monthly polyarthritis attacks were accompanied by subcutaneous tophi. Serum uric acid levels were constantly above 600??mol/L (10?mg/dL). Allopurinol was no option because of intolerance, while benzbromarone was ineffective because of renal impairment. Therefore, the novel xanthin oxidase inhibitor febuxostat was started, achieving rapid control of serum urate levels (<360??mol/L). After initial worsening of inflammation in the first weeks, gouty attacks stopped and all tophi resolved within the following 10 months. Renal function remained stable.
Related JoVE Video
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research.
Ann. Rheum. Dis.
PUBLISHED: 02-01-2011
Show Abstract
Hide Abstract
The European League Against Rheumatism Scleroderma Trials and Research Group (EUSTAR) has established an online database with clinical data of currently more than 8200 patients with systemic sclerosis (SSc). In addition to clinical research, EUSTAR fosters biomolecular studies to develop novel biomarkers and therapies for SSc. High-quality biospecimens are the basis for successful biomolecular studies. The EUSTAR biobanking group has therefore developed recommendations to standardise the collection, storage and distribution of SSc biospecimens at EUSTAR centres. These recommendations consider the scientific challenges associated with biomolecular research in SSc and the organisational requirements of EUSTAR. They were approved by the EUSTAR executive committee as well as the EUSTAR board. Once they become effective, these recommendations will be the basis for international EUSTAR studies with large numbers of SSc biospecimens. These recommendations might also be followed by other SSc consortia to enable exchange of biosamples between different SSc initiatives and might serve as a template for biobanking initiatives in other rheumatic diseases.
Related JoVE Video
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity.
Semin. Arthritis Rheum.
PUBLISHED: 01-29-2011
Show Abstract
Hide Abstract
To determine if mixed connective tissue disease (MCTD) can be considered an independent clinical entity, to compare 3 different classification criteria for MCTD (Kasukawa, Alarcón-Segovia, and Sharp), and to define predictors (clinical features and autoantibodies) of potential evolution toward other connective tissue diseases (CTDs).
Related JoVE Video
Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients.
Rheumatology (Oxford)
PUBLISHED: 09-11-2009
Show Abstract
Hide Abstract
To follow-up on all available infliximab-treated SLE patients for safety and long-term efficacy in order to extract information that is useful for planning appropriate controlled trials with infliximab in SLE.
Related JoVE Video
Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells.
Arthritis Rheum.
PUBLISHED: 05-01-2009
Show Abstract
Hide Abstract
To investigate interferon-gamma (IFNgamma) signaling in peripheral blood mononuclear cells (PBMCs) from patients with systemic lupus erythematosus (SLE) by analyzing IFNgamma receptor (IFNgammaR) expression, STAT-1 expression and phosphorylation, and the regulation of IFNgamma-inducible genes.
Related JoVE Video
Gout--current diagnosis and treatment.
Dtsch Arztebl Int
PUBLISHED: 01-19-2009
Show Abstract
Hide Abstract
Because of the changing dietary habits of an aging population, hyperuricemia is frequently found in combination with other metabolic disorders. Longstanding elevation of the serum uric acid level can lead to the deposition of monosodium urate crystals, causing gout (arthritis, urate nephropathy, tophi). In Germany, the prevalence of gouty arthritis is estimated at 1.4%, higher than that of rheumatoid arthritis. There are no German guidelines to date for the treatment of gout. Its current treatment is based largely on expert opinion.
Related JoVE Video
Identification of relevant concepts of functioning in daily life in people with systemic lupus erythematosus: A patient Delphi exercise.
Arthritis Rheum.
PUBLISHED: 01-01-2009
Show Abstract
Hide Abstract
To identify the most important and relevant concepts of daily functioning from the perspective of patients with systemic lupus erythematosus (SLE).
Related JoVE Video
Relevant incidence of cervical arthritis in patients with erosive seropositive rheumatoid arthritis even today.
Clin. Exp. Rheumatol.
Show Abstract
Hide Abstract
This paper aims to investigate adherence to, and outcome of, radiographic screening of patients with rheumatoid arthritis (RA) for cervical involvement, given the availability of state of the art disease-modifying anti-rheumatic drug (DMARD) and biological therapies.
Related JoVE Video
Innate immune processes in lupus erythematosus.
Clin. Immunol.
Show Abstract
Hide Abstract
The innate immune system is involved in the pathogenesis of systemic autoimmune diseases such as systemic lupus erythematosus (SLE) or dermatomyositis. The important role of complement factors of the classical pathway and of Toll like receptors (TLRs) is well established, based on genetic and clinical evidence. Immune complexes activate tumor necrosis factor (TNF) in myeloid cells and interferon-? (IFN?) in plasmacytoid dendritic cells. The latter initiates a positive feedback loop that drives autoimmunity. More recently, mutations in genes encoding intracellular enzymes involved in RNA and DNA handling, which likewise lead to increased IFN?, have been found to cause familial chilblain lupus and to be associated with SLE. Within the immunological disease continuum, these disorders can be placed between autoinflammation and autoimmunity, and we would propose the term autoadjuvant for this group, since the activation of the innate immune system in these diseases appears to lower the threshold for (auto)immune reactions.
Related JoVE Video
Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
J. Rheumatol.
Show Abstract
Hide Abstract
Rituximab (RTX) therapy is a treatment option in patients with refractory antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). We investigated the tolerability and clinical efficacy of RTX in a cohort of patients with refractory AAV.
Related JoVE Video
Performance of the 2011 ACR/EULAR preliminary remission criteria compared with DAS28 remission in unselected patients with rheumatoid arthritis.
Ann. Rheum. Dis.
Show Abstract
Hide Abstract
To compare the performance of the preliminary American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) remission criteria with the 28-joint count Disease Activity Score (DAS28) remission in unselected real-life patients.
Related JoVE Video
Role of interleukin-6 in stress, sleep, and fatigue.
Ann. N. Y. Acad. Sci.
Show Abstract
Hide Abstract
Chronic low-grade inflammation, in particular increased concentrations of proinflammatory cytokines such as interleukin (IL)-6 in the circulation, is observed with increasing age, but it is also as a consequence of various medical and psychological conditions, as well as life-style choices. Since molecules such as IL-6 have pleiotropic effects, consequences are wide ranging. This short review summarizes the evidence showing how IL-6 elevations in the context of inflammatory disease affect the organism, with a focus on sleep-related symptoms and fatigue; and conversely, how alterations in sleep duration and quality stimulate increased concentrations of IL-6 in the circulation. Research showing that acute as well as chronic psychological stress also increase concentrations of IL-6 supports the notion of a close link between an organisms response to physiological and psychological perturbations. The findings summarized here further underscore the particular importance of IL-6 as a messenger molecule that connects peripheral regulatory processes with the CNS.
Related JoVE Video
International cohort study of 73 anti-Ku-positive patients: association of p70/p80 anti-Ku antibodies with joint/bone features and differentiation of disease populations by using principal-components analysis.
Arthritis Res. Ther.
Show Abstract
Hide Abstract
An international cohort study of 73 anti-Ku-positive patients with different connective tissue diseases was conducted to differentiate the anti-Ku-positive populations of patients based on their autoantibody profile and clinical signs/symptoms and to establish possible correlations between antibodies against Ku p70 and Ku p80 with autoimmune diseases.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.